- The MoU aims to investigate how Artificial
Intelligence can be used to support the diagnosis of breast cancer, especially
in improving early breast cancer detection.
- The study is divided into two parts, retrospective and
prospective; and will be facilitated by Radiology Across Borders.
Today, Siemens Healthineers announced its collaboration with Hanoi Medical University Hospital (HMUH) and Radiology Across Borders (RAB), on the application of Artificial Intelligence (AI) in mammography, to screen abnormal lesions in the breast. The MoU signing was attended by Mr. Fabrice Leguet, Managing Director, Siemens Healthineers Southeast Asia; Assoc. Prof. PhD. Dr. Nguyen Lan Hieu, Director, HMUH; PhD. Dr Le Tuan Linh, Director, HMUH Center for Diagnostic Imaging and Interventional Radiology; Dr. Suresh de Sliva, Founder and Chairman, RAB; Dr. Katja Beitat, Director/Company Secretary, RAB and representatives from the three organizations.
According to GLOBOCAN, 21,555 new cases of
breast cancer and more than 9,000 deaths from breast cancer, were reported in
Vietnam in the year 20201. Breast cancer is the second leading cause of cancer
related deaths for women around the world, often occurring with few warning
signs. Early detection of this disease increases the number of available
treatment options, improving survival rates and the quality of life of breast
cancer patients. Mammography is the X-ray of mammary glands for the purpose of
diagnosis of lumps and tumors of the breasts. This technique allows the
structure of the mammary gland to be analyzed
to find any abnormality within the breast that usually cannot be detected by
manual examination.
According to the Radiological Society of North
America, the use of advanced techniques like AI, can enhance the
performance of radiologists by increasing breast cancer detection rate as
compared to manual screening. While AI cannot
replace radiologists, the use of this technology can help reduce reading time for each mammography screening, allowing for
greater attention to be directed towards suspicious cases, while improving
efficiency2. This joint collaboration is an important milestone to
effectively demonstrate the benefits of AI for supporting radiologists in
Vietnam and many other nations with similar healthcare systems in the
developing world.
Speaking at the MoU Signing Ceremony, Assoc. Prof. PhD. Dr. Nguyen Lan Hieu, Director, Hanoi MUH expressed high appreciation for the collaboration between the parties and shared his views, ideas, and expectations for the study. He said, "We receive thousands of patients yearly for examination and treatment of breast tumors. The workload and pressure on processing times and expectation for accurate detection on medical staff is enormous. To cope with our heavy workload and improve our patient care, the application of advanced technologies like AI to the workflow is necessary. This collaboration with Siemens Healthineers and RAB has great clinical significance to us, and thus, greatly contribute in serving Vietnamese's people.”
“We are proud to be partnering with one of the most prominent hospitals in Vietnam - the Hanoi Medical University Hospital along with our partner, Radiology Across Borders. Together, we strive to show that AI can help in early and accurate detection of breast abnormalities and also free up radiologist resources, thereby giving more patients the opportunity to access high quality care. We at Siemens Healthineers, pioneer breakthroughs in healthcare. For Everyone. Everywhere. This collaboration with HMUH and RAB further exemplifies our pioneering breakthroughs in improving the health of women in Vietnam”, said Mr. Fabrice Leguet, Managing Director, Siemens Healthineers Southeast Asia.
Siemens Healthineers will provide Transpara Breast AI solution to HMUH as part of this collaboration. The collaboration between the three organizations will take effect within 24 months, with a 12-month extended option and will be facilitated by RAB. RAB will assist in the setup and running of the pilot, as well as provide general expert clinical advice in breast imaging.
About Siemens Healthineers
Siemens Healthineers AG (listed Frankfurt, Germany0: SHL) is pioneering breakthroughs in Healthcare. For Everyone. Everywhere. As a leading medtech company, headquartered in Erlangen, Siemens Healthineers, through its regional companies, enable healthcare providers around the world to increase value by supporting them in their journey towards expanding precision medicine, transforming care delivery, improving patient experience, and digitalizing healthcare. Siemens Healthineers continuously improves its products and services portfolios, and its applications that combine artificial intelligence and digitalization that play a key role in the next step of medical technology. These new applications help strengthen the company's foundation in the areas of imaging, interventional and laboratory therapy, and cancer treatment. Siemens Healthineers also offers a range of services and solutions to help healthcare providers improve their capacity to deliver better quality and efficient healthcare to patients. By the end of Fiscal year 2021 (30 September 2021), the company generated 18 billion EUR revenues. Following the acquisition with Varian Health Systems, the company now has approximately 66,000 employees globally. For more information, please visit: www.siemens-healthineers.com/vn
Press Contact
Ms. Nguyen Thi Ngoc Yen
Head of Marketing and Communications
Siemens Healthineers
Phone : +84 904 591 769